Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607957 · ClinicalTrials.gov registry record · Phase 3
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
A Phase 3 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT01607957 is a Phase 3 study that has completed, run by Taiho Oncology. The registered enrollment target is 800 participants.
The verdict
NCT01607957, a Phase 3 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
Interventions
- DRUG Placebo
- DRUG TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2012-06-17 |
| Est. Completion | 2016-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01607957
The ClinicalTrials.gov registry entry for NCT01607957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01607957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01607957 about?
NCT01607957 is a clinical study titled "Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies". The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
What is the current status of trial NCT01607957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2012-06-17. Estimated completion is 2016-05-23.
What interventions are being tested in trial NCT01607957?
The interventions under investigation include: Placebo (DRUG), TAS-102 (DRUG).
Who is sponsoring clinical trial NCT01607957?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.